Wedge Industrial (000534) Q4 2025 earnings summary

Executive summary

• Achieved revenue of ¥1.29 billion in 2025, up 19.62% year-over-year; net profit attributable to shareholders rose 2.22% to ¥197 million.

• Main businesses: microecological active bacteria products and high-temperature alloy R&D, production, and sales.

• Significant R&D and market expansion in both pharmaceutical and high-temperature alloy segments.

Financial highlights

• Revenue: ¥1,290,501,146.98 (+19.62% YoY); net profit attributable to shareholders: ¥197,018,496.61 (+2.22% YoY).

• Gross margin for pharmaceutical manufacturing: 90.97%; for high-temperature alloys: 21.15%.

• Total assets at year-end: ¥4,589,777,946.02 (+15.60% YoY); net assets: ¥1,603,332,822.53 (+17.81% YoY).

• Basic EPS: ¥0.3975; diluted EPS: ¥0.3887.

• R&D investment: ¥236.34 million, 18.31% of revenue.

Outlook and guidance

• 2026 focus: high-quality growth, cost reduction, efficiency improvement, and digital transformation.

• Pharmaceutical segment to accelerate clinical trials and product upgrades; alloy segment to enhance R&D and expand market share.

• Continued investment in dual-base construction and digitalization.